CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025)

CRISPR Therapeutics AG has disclosed Change in Receivables across 10 years of filings, most recently posting -$25.0 million for Q1 2025.

• In Q1 2025, Change in Receivables rose 87.5% year-over-year to -$25.0 million; the TTM figure through Dec 2025 stood at -$25.0 million (up 85.71% YoY), while the FY2025 annual figure was -$25.0 million, up 85.71% from the prior year.
• Change in Receivables came in at -$25.0 million for Q1 2025 at CRISPR Therapeutics AG, down from $25.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $200.0 million in Q4 2023 to a low of -$200.0 million in Q1 2024.
• Average Change in Receivables over 5 years is -$11076.9, with a median of -$17000.0 recorded in 2022.
• The largest YoY upside for Change in Receivables was 408263.27% in 2023 against a maximum downside of 411664.71% in 2023.
• Over 5 years, Change in Receivables stood at $153000.0 in 2021, then sank by 132.03% to -$49000.0 in 2022, then jumped by 408263.27% to $200.0 million in 2023, then sank by 87.5% to $25.0 million in 2024, then plunged by 200.0% to -$25.0 million in 2025.
• Per Business Quant data, the three most recent Change in Receivables figures were -$25.0 million in Q1 2025, $25.0 million in Q4 2024, and -$200.0 million in Q1 2024.